RT @WileyNeuro: This updated @CochraneLibrary systematic review on Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy from @…
This updated @CochraneLibrary systematic review on Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy from @CochraneEpileps looks at the evidence from 7 clinical trials with 2185 participants. Learn more: https://t.co/6V7eooB25d https://t
RT @CochraneIberoam: 📰 Acetato de eslicarbazepina como tratamiento complementario para la #epilepsia focal resistente a los medicamentos ht…
RT @CochraneIberoam: 📰 Acetato de eslicarbazepina como tratamiento complementario para la #epilepsia focal resistente a los medicamentos ht…
📰 Acetato de eslicarbazepina como tratamiento complementario para la #epilepsia focal resistente a los medicamentos https://t.co/RuTkNrwIoI Revisión actualizada de @CochraneEpileps que analiza la #evidencia de 7 ensayos clínicos. #systematicreviews #rev
RT @WileyHealth: This updated @CochraneLibrary systematic review on Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy from…
This updated @CochraneLibrary systematic review on Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy from @CochraneEpileps looks at the evidence from 7 clinical trials with 2,185 participants. Learn more: https://t.co/ST38Uwk0Q8 https://t
RT @CochraneUK: Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy https://t.co/WzM28mbnGY Updated systematic review from @C…
RT @CochraneUK: Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy https://t.co/WzM28mbnGY Updated systematic review from @C…
Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy https://t.co/nIpZHgVjSS Updated systematic review from @CochraneEpileps looks at the evidence from 7 clinical trials with 2185 participants.
Eslicarbazepine acetate add‐on for drug‐resistant focal #epilepsy. Read our recently updated systematic review which looks at the evidence from 7 clinical trials with 2185 participants. https://t.co/cF25JSjbpc https://t.co/AdNCcySMx7